酰基辅酶A硫酯酶9在肝脏中将线粒体短链脂肪酸导向从头脂肪生成和葡萄糖生成
该研究通过秀丽隐杆线虫筛选发现Acot9是Acot家族中调节脂质积累最强的成员;肥胖合并NAFLD/NASH患者肝脏Acot9表达高于健康肥胖对照;小鼠全局敲除Acot9可抵抗体重增加、肝葡萄糖生成、脂肪变性和脂肪性肝炎,而肝脏特异性敲除抑制肝葡萄糖生成和脂肪变性但不影响饮食诱导的体重增加;机制上Acot9定位于线粒体内膜,使短链而非长链脂酰辅酶A脱酰基,将乙酰辅酶A从蛋白赖氨酸乙酰化导向三羧酸循环,从而为肝葡萄糖生成和从头脂肪生成提供底物。
要点
- 肥胖合并NAFLD/NASH患者肝脏Acot9表达高于健康肥胖对照。
- 小鼠全局敲除Acot9可抵抗体重增加、肝葡萄糖生成、脂肪变性和脂肪性肝炎。
- Acot9定位于线粒体内膜,使短链而非长链脂酰辅酶A脱酰基,将乙酰辅酶A导向三羧酸循环。
核心结论
- Acot9在肥胖病理生理状态下将肝脏酰基辅酶A导向增加的肝葡萄糖生成和从头脂肪生成,因此Acot9是管理NAFLD的靶点。
研究设计与样本
- 利用秀丽隐杆线虫鉴定Acot家族中调节脂质积累最强的成员,并在肥胖合并NAFLD/NASH患者与健康肥胖对照中比较肝脏Acot9表达,在小鼠中进行全局敲除、肝脏特异性敲除和肝脏 rescue 实验。
主要发现
- 在Acot家族中,Acot9被鉴定为脂质积累最强的调节因子。
- 肥胖合并NAFLD和NASH患者肝脏Acot9表达高于健康肥胖对照。
- 在过度营养状态下,全局敲除Acot9保护小鼠抵抗体重增加、肝葡萄糖生成、脂肪变性和脂肪性肝炎的增加。
- 肝脏特异性敲除Acot9抑制小鼠肝葡萄糖生成和脂肪变性,且不影响饮食诱导的体重增加。
- 仅在Acot9敲除小鼠肝脏中恢复Acot9表达足以促进肝葡萄糖生成和脂肪变性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Obesity-induced pathogenesis of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) is associated with increased de novo lipogenesis (DNL) and hepatic glucose production (HGP) that is due to excess fatty acids. Acyl-coenzyme A (CoA) thioesterase (Acot) family members control the cellular utilization of fatty acids by hydrolyzing (deactivating) acyl-CoA into nonesterified fatty acids and CoASH. APPROACH AND RESULTS: Using Caenorhabditis elegans, we identified Acot9 as the strongest regulator of lipid accumulation within the Acot family. Indicative of a maladaptive function, hepatic Acot9 expression was higher in patients with obesity who had NAFLD and NASH compared with healthy controls with obesity. In the setting of excessive nutrition, global ablation of Acot9 protected mice against increases in weight gain, HGP, steatosis, and steatohepatitis. Supportive of a hepatic function, the liver-specific deletion of Acot9 inhibited HGP and steatosis in mice without affecting diet-induced weight gain. By contrast, the rescue of Acot9 expression only in the livers of Acot9 knockout mice was sufficient to promote HGP and steatosis. Mechanistically, hepatic Acot9 localized to the inner mitochondrial membrane, where it deactivated short-chain but not long-chain fatty acyl-CoA. This unique localization and activity of Acot9 directed acetyl-CoA away from protein lysine acetylation and toward the citric acid (TCA) cycle. Acot9-mediated exacerbation of triglyceride and glucose biosynthesis was attributable at least in part to increased TCA cycle activity, which provided substrates for HGP and DNL. β-oxidation and ketone body production, which depend on long-chain fatty acyl-CoA, were not regulated by Acot9. CONCLUSIONS: Taken together, our findings indicate that Acot9 channels hepatic acyl-CoAs toward increased HGP and DNL under the pathophysiology of obesity. Therefore, Acot9 represents a target for the management of NAFLD.
引用
- Steensels S, Qiao J, Zhang Y, et al. Acyl-Coenzyme A Thioesterase 9 Traffics Mitochondrial Short-Chain Fatty Acids Toward De Novo Lipogenesis and Glucose Production in the Liver. Hepatology. 2020. PMID: 32498134. doi:10.1002/hep.31409
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。